fostamatinib sold brand names tavalisse tavlesse tyrosine kinase inhibitor medication treatment chronic immune thrombocytopenia drug administered fostamatinib blocks activity enzyme spleen tyrosine kinase enzyme involved stimulating parts immune blocking syks activity fostamatinib reduces immune systems destruction platelets allowing platelet count rise reduces likelihood excessive commonly reported side effects diarrhea high blood pressure nausea respiratory infection dizziness increased liver enzymes rash abdominal pain fatigue chest pain decreased white blood cell us food drug administration fda considers firstinclass fostamatinib drug used treat adults low platelet count due chronic immune thrombocytopenia itp prior treatment itp worked well enough chronic immune thrombocytopenia autoimmune bleeding disorder blood doesnt clot low platelet tablets formulated fostamatinib disodium hexahydrate disodium hexahydrate salt prodrug active compound tamatinib inhibitor enzyme spleen tyrosine kinase hence syk inhibitor syk protein tyrosine kinase associated various inflammatory cells including macrophages presumed cells responsible itp platelet fcγrs iia iiia bind ligands receptor complex becomes activated triggers phosphorylation immunoreceptoractivating motifs itams leads various genes becoming activated causes cytoskeletal rearrangement mediates phagocytosis cells monocytemacrophage lineage syk plays important role fcγrmediated signal transduction inflammatory propagation considered good target inhibition various autoimmune conditions including rheumatoid arthritis lymphoma fostamatinib clinical trials rheumatoid arthritis autoimmune thrombocytopenia autoimmune hemolytic anemia iga nephropathy drug currently used phase trail test safety combination study drugs fostamatinib paclitaxel patients ovarian investigation fostamatinib began studies involving treatment mouse models cytopenia mice used measure effectiveness small molecule prodrug biologically active syk inhibitor animal models treatment shown safe effective reducing inflammation joint damage immunemediated rheumatoid arthritis models responded favorably treatment study progressed phase trials involving humans human studies shown good oral bioavailability biologic activity well tolerated exhibit collagen adpinduced platelet aggregation adults chronic itp entered openlabel singlearm cohort doseescalation trials beginning mg rising mg twice day dose increased persistent response evident toxicity reached mg twice day met patients achieved persistent responses platelet counts greater visits patients persistently responded thrombopoietic agents others nonsustained responses mean peak platelet count exceeded patients toxicity evidenced primarily girelated side effects notable diarrhea urgency vomiting patients developed fostamatinib treatment severe complications finished phase trial entering phase trial phase ii study rheumatoid arthritis patients failing respond biologic agent showed little efficacy compared placebo drug well tolerated patients high inflammatory burden measured levels creactive protein achieved significantly higher portion fostamatinib group versus placebo group immune thrombocytopenic purpura itp autoimmune disease immune system attacks destroys platelets blood causing abnormally low platelet counts characterized antibodymediated destruction platelets patients itp accelerated clearance circulating iggcoated platelets via fcγ receptorbearing macrophages spleen liver leading different levels thrombocytopenia variable degrees mucocutaneous recent studies itp pathophysiology suggest decreased platelet production may also important component thrombocytopenia many patients exhibit responses established therapies including corticosteroids iv immunoglobulin antid splenectomy rituximab however significant minority patients retain persistently low platelet counts despite treatment patients consistently risk intracranial hemorrhage bleeding complications several thrombopoiesisstimulating therapies including eltrombopag romiplostim investigated help combat low platelet counts itp patients rigel reported results two phase iii clinical trials fostamatinib itp treatment august october study second phase multicenter randomized doubleblind placebo controlled study fostamatinib disodium treatment persistentchronic immune thrombocytopenic purpura rigel conducted primary outcome measures defined stable platelet response end study week least least visits weeks participants received either placebo mg mg drug morning evening full weeks first study fit met primary endpoint statistically significant manner patients hitting plateletsμl blood patients receiving placebo meeting criteria june openlabel long term extension study currently tracking patients opted receive fostamatinib completing either study approval treatment autoimmune hemolytic anemia aiha stage phase ii trials study phase multicenter open label simon twostage study evaluate safety efficacy fostamatinib disodium treatment warm antibody autoimmune hemolytic anemia primary outcome measures examined include hemoglobin response measured levels higher gdl gdl higher baseline hemoglobin responses studied period weeks dose mg morning evening study began april estimated conclude september study currently recruiting participants us states including arizona california dc massachusetts new york north carolina texas subjects must diagnosis primary secondary warm antibody aiha must failed least prior treatment regimen aiha subjects platelet count less aiha secondary autoimmune disease uncontrolled poorly controlled hypertension cold antibody aiha cold agglutinin syndrome mixed type aiha paroxysmal cold fostamatinib treatment iga nephropathy igan phase ii trials conclude end igan chronic autoimmune disease associated inflammation kidneys reduces ability successfully filter blood currently diseasetargeted therapies igan participants currently recruited us austria germany hong kong taiwan uk patients must years old renal biopsy findings consistent iga nephropathy treated angiotensin converting enzyme inhibitor acei andor angiotensin ii receptor blocker arb least days maximum approved dose proteinuria gmday diagnosis iga nephropathy level gmday second screening visit blood pressure controlled angiotensin blockade eligible candidates recently used cyclophosphamide mycophenolate mofetil azathioprine rituximab mgday prednisone corticosteroid equivalent study investigates whether fostamatinib safe effective treatment igan phase multicenter randomized doubleblind ascendingdose placebocontrolled clinical study primary outcome measures include mean change proteinuria measured spot urine proteincreatinine ratio spcr effects evaluated mg mg placebo formulations taken twice daily mouth weeks study began october expected complete june fostamatinib approved medical use united states april us food drug administration fda approved fostamatinib based evidence two identical doubleblind placebocontrolled clinical trials adults persistent chronic itp insufficient response previous treatment included corticosteroids immunoglobulins splenectomy andor thrombopoietin receptor participants allowed continue previous itp treatment patients randomized fostamatinib mg orally twice daily placebo twice daily dose could escalated mg orally twice daily one benefit fostamatinib assessed based percentage participants achieved maintained predetermined platelet count treatment weeks fostamatinib placebo groups trial conducted sites australia canada denmark hungary italy netherlands united kingdom united trial conducted sites austria bulgaria czech republic germany norway poland romania fda granted application fostamatinib orphan drug granted approval tavalisse rigel fostamatinib approved medical use european union january httpsenwikipediaorgwikifostamatinib